NOVADIP Biosciences S.A.

🤔 Planning to attend #LSIUSA2025 in March? Don’t miss Denis Dufrane, CEO of Novadip, as he takes the stage on March 20 to share insights on our groundbreaking orthopedic solutions. He’ll be discussing how our innovations are transforming the healing of bone defects, spinal fusion, and more! Get all the details below 👇

🚀 We are proud to share that Denis Dufrane has been selected to present NOVADIP Biosciences S.A. at LSI USA ’25, March 17-21, 2025.    💥 Denis will present on March 20 at 10:30 AM - a unique opportunity for attendees to learn about Novadip's proprietary technology platform and discover how our regenerative tissue products are transforming the healing of large bone defects, non-union fractures, and spine fusion in a single treatment.   🤝 We look forward to engaging with fellow professionals and exploring potential collaborations.  💬 Send us a message to arrange a meeting with Denis at the event   #medtech #innovation #RegenerativeMedicine #Orthopedics #BoneHealing #LSI2025   https://lnkd.in/dQiNk4np

We are thrilled to announce the appointment of Drew Trivisonno to our Board of Directors 👏   With over three decades of expertise in debt and equity financing, plus 18 years as a leader in M&A, financing transactions, and building strategic partnerships, Drew is an exceptional addition to the Novadip team.    His experience will be pivotal as we accelerate our growth and move forward with our bold 2025 strategy, including a €50M Series C and a major expansion in the US #orthopedics market 🌍💡   “I am excited to join the Novadip board. The company’s clinical results have been outstanding, with NVD003 showing strong promise in pediatric patients and NVDX3 having excellent results in adults. This puts Novadip in a great position to become a world-leader in bone healing. I look forward to working with Denis and the entire Novadip team,” said Mr. Trivisonno.   Welcome to the team, Drew!    More info in this news release: https://lnkd.in/e2xKzcbP Denis Dufrane Eric Paul Pâques   #Appointment #Finance #RegenerativeMedicine #BoneHealing

 ✨ The Novadip team wishes you a happy and successful New Year! 🇺🇸 To kick off January, we are thrilled to announce that our CEO Denis Dufrane will be attending the J.P. Morgan Healthcare Conference in San Francisco next week to meet potential investors and partners, preparing for our Series C financing round targeting €50M. 💬 Drop us a message if you would like to arrange a meeting with Denis on Jan 13-16, to discuss our 3M3 tissue regeneration platform and the start of 3 pivotal trials in the US and in the EU for both our autologous and allogenic bone products. #RegenerativeMedicine #BoneHealing #Orthopedics #JPMorganHealth #JPM2025

  🗓️ With 2024 soon coming to an end, we are proud to reflect on a year of clinical excellence for NOVADIP Biosciences S.A. 🚀 2024 has been a year of clinical breakthroughs for Novadip: 👥 Following collaborative meetings with the FDA and European Medicines Agency, we are now ready to take our lead autologous therapy, NVD003, into a pivotal phase 3 for the treatment of congenital pseudoarthrosis of the tibia (CPT), a rare pediatric bone condition. 💪 NVD003 gained recognition from the European Commission for its potential to change lives. 🦴 We obtained positive interim results from our phase 1b/2a first-in-human trial for NVDX3 to heal distal radius fractures showing 90% of adult patients with these fractures reaching or steadily progressing towards complete bone healing at 6 months. ✅ Based on this promising safety and efficacy data, we received FDA approval for our Investigational New Drug Application (IND) for NVDX3 to move directly into a phase 2b trial in cervical spinal fusion, marking a big step forward in NVDX3’s development. 🌎 Our CEO Denis Dufrane and the team took our scientific work global, presenting at several international events including BIO International Convention in San Diego, LSI USA 24, Advanced Therapies in Belgium and The State of Spine Surgery 2024 meeting held in Mexico.  🥼 We strengthened our clinical advisory board welcoming Dr Alexander Ropper, Director of Spinal Neurosurgery at Bayer College of Medicine, to the team. In addition:  💶 We raised €9.6M for two collaborative projects focusing on ATMPs to accelerate the development of nanovesicle-based therapeutics for oncology and regenerative medicine purposes based on our 3M3 platform BioWin. As we look ahead to 2025, we are excited to continue pioneering innovative regenerative therapies to transform bone healing. Thank you to our dedicated team, advisors, partners, investigators, and patients for supporting our mission!   #biotech #clinicaltrial #regenerativemedicine #stemcells #celltherapy 

2025 is just around the corner and so is #LSIUSA25 🚀 We are thrilled to participate in LSI USA on March 17-21 to showcase our proprietary technology platform designed to develop a new class of regenerative tissue products that accelerate healing of large bone defects, bone non-union and spine fusion in a single treatment. Many thanks to LSI USA for this highlight, looking forward to meeting partners, investors and fellow innovators at this unique event shaping the future of the healthtech industry Denis Dufrane #medtech #innovation #RegenerativeMedicine https://lnkd.in/ezEe3uvf

13 years after reconstruct a patient following an osteosarcoma’s resection with our first autologous Tissue engineered product, Hara (VP R&D) presented the potential of our platform to cure the bone tumors. Very proud

News release // New milestone for Novadip Biosciences We are thrilled to announce that Novadip’s NVDX3 has reached key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion 📅Key trial details: • Phase 2b/3 study expected to begin enrollment in H2 2025 across 10 sites in the US. • The FDA-approved IND study will assess the efficacy of NVDX3 compared to standard-of-care treatments in level two cervical spine fusion 📣 Denis Dufrane, MD, PhD, CEO of Novadip, explains: “The trial will accelerate our capability to bring NVDX3 to patients with complex needs, providing them with a better chance of healing compared to standard-of-care treatments. These strategic steps enable us to take NVDX3 to the next level.” Built upon robust preclinical and clinical data, NVDX3 is poised to disrupt current treatment options by offering a single treatment solution for patients at high risk of nonunion due to complex comorbidities such as aging, diabetes, obesity, and smoking. 👉 Stay tuned for more clinical updates #RegenerativeMedicine #SpinalFusion #BoneHealing #ClinicalTrials #CervicalSpineFusion

📣 Online event // Our CEO Denis Dufrane will be participating in the European Commission online event on the “Implementation of the Hospital Exemption in the EU and its role in boosting innovation and patient access to innovative therapies” this Thursday, Nov 21, at 3:40pm. This event will bring together a wide range of experts and representatives from academia, the biotech industry, professional organizations and national authorities to explore the impact of the Hospital Exemption pathway on patient access to #ATMP. 🔬Novadip is a pioneer in the implementation of the Hospital Exemption rule in Belgium, which allowed us to develop our innovative therapy NVD003 to avoid amputation in children with congenital tibial pseudarthrosis. Join us this Thursday to follow Denis’ session “Supporting academic developers of ATMPs and competitiveness of the EU biotech sector” 👉 https://lnkd.in/dgK2jnia   #biotech #innovation #regenerativemedicine

🗞️ Our CEO Denis Dufrane spoke with Orthopedics This Week about the excellent results from our first-in-human proof-of-concept Trauma Study into the safety and efficacy of NVDX3, a unique “Off the Shelf” allogeneic matrix product to cure common but challenging orthopedic conditions. Read the full interview with Denis👇 https://lnkd.in/gg3bpyfz #biotech #clinicaltrial #orthopedics #regenerativemedicine #stemcells #celltherapy